HOME >> MEDICINE >> NEWS
New data shows ACTOS reduced heart attacks by 28 percent in people with type 2 diabetes

New results from secondary analyses of the landmark PROactive Study found that ACTOS (pioglitazone HCl) significantly reduced the occurrence of fatal and non-fatal heart attacks and acute coronary syndrome (ACS) in high-risk patients with type 2 diabetes who had a previous heart attack. Importantly, these results were above and beyond those seen with standard of care treatment.

The findings, which were revealed today at the American Heart Association's Scientific Sessions 2005, build on previously-reported results from the PROactive Study, showing that ACTOS, an oral antidiabetic medication, significantly reduced the combined risk of heart attacks, strokes and death by 16 percent in high-risk patients with type 2 diabetes.

"Takeda is breaking new ground with the PROactive Study. Never before have this many high-risk people with type 2 diabetes and cardiovascular disease been studied," said Robert Spanheimer, M.D., medical director for diabetes and metabolism at Takeda Pharmaceuticals North America. "Through this innovative research, we now know that ACTOS can markedly reduce the recurrence of heart attacks."

These data assessed the effects of ACTOS on cardiovascular morbidity and mortality in 2,445 high-risk patients who had previously had a heart attack, a population that tends to have a very poor prognosis. The results show that in patients taking ACTOS on top of standard of care treatment:

  • The recurrence of fatal or non-fatal heart attacks was reduced by 28 percent (P =0.045)
  • The risk of acute coronary syndrome or ACS (a term used to describe potentially life-threatening, acute cardiovascular events) was reduced by 37 percent (P =0.035)
  • There was a 19 percent (P=0.034) risk reduction in the cardiac composite endpoint of non-fatal heart attacks, coronary revascularization, ACS and cardiac death

"These results are very meaningful for the diabetes community, especially w
'"/>

Contact: Jocelyn Gerst
jgerst@tpna.com
847-769-6889
Ketchum
16-Nov-2005


Page: 1 2 3

Related medicine news :

1. New study shows promise in reducing surgical risks associated with surgical bleeding
2. Most seniors now have drug coverage, U-M study shows
3. Wireless technology shows promise in diagnosing pediatric intestinal disease
4. Study shows radiofrequency ablation highly effective in treating kidney tumors
5. Method shows promise for early detection of pancreatic cancer
6. Organic farming can feed the world, U-M study shows
7. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
8. Borderline personality disorder shows improvements with intensive psychotherapy
9. New drug shows promise in treatment of advanced thyroid cancer
10. Study shows Diachrome improves blood sugar control in people with type 2 diabetes
11. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy

Post Your Comments:
(Date:6/19/2013)... 19, 2013 Amerinet, Inc, a ... Healthcare Technologies to help Pacific Medical Centers implement ... of more than 17 percent over the organization’s ... , “Driving economies of scale and process standardization ... challenges facing multi-site providers,” said Shawn Padilla, director ...
(Date:6/19/2013)... Elsevier, a world-leading provider of scientific, technical ... the publication of the National Osteoporosis Guideline Group ... osteoporosis in postmenopausal women and older men in ... 2009 in Maturitas , the original guidelines ... timely with an additional focus on the management ...
(Date:6/19/2013)... June 19, 2013 Imprivata ®, ... today announced that Imprivata OneSign ® leads the ... Mid-Term Performance Review: Software & Services report . CIOs ... Imprivata on the superior performance of its products and ... they indicate that Imprivata is integral to their long-term ...
(Date:6/19/2013)... 2013 According to Transparency Market Research ... Trends, Analysis and Forecast, 2011 – 2017,” the global ... the year 2011 and is expected to reach USD ... 9.7% from 2011 to 2017. Flexible endoscopes formed the ... USD 2,201 million for the year 2011. , Related ...
(Date:6/19/2013)... Despite the fact that the incidence of cancer is ... age, we still have an inadequate understanding on how ... though elderly patients are occasionally included in clinical trials, ... ,healthy, (fit) elderly patients. Thus, the broader elderly patient ... EORTC Cancer in the Elderly Task Force is now ...
Breaking Medicine News(10 mins):Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2
(Date:6/19/2013)... CARLSBAD, Calif. , June 19, 2013 /PRNewswire/ ... ) today announces a licensing agreement granting Suzhou ... develop and manufacture siRNA therapeutics in ... technology.  Ribo will formulate proprietary siRNA molecules in ... platform designed to address human diseases with high ...
(Date:6/19/2013)... may seem like an odd pairing: an oral growth hormone-boosting ... two of the most talked about topics at ENDO 2013, ... that just convened in San Francisco . ... the top internal medicine experts in the world is very ... not only save lives, but help people feel and ...
(Date:6/18/2013)... MT. PROSPECT, Ill. , June 18, 2013 ... availability of its new X3130 Appliance Inlet Module. ... thermal circuit breaker , combines a C14 appliance ... in one compact package.  This three-in-one device allows ... in their designs - cutting installation time by ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Three-in-One X3130 Appliance Inlet Module 2
Cached News: